Click Therapeutics Unveils New Brand Identity to Strengthen Leadership in Software as Prescription Treatments
Click Therapeutics, Inc. (“Click”), a pioneer in the development of prescription medical treatments, has unveiled a new brand identity and website to reflect its evolution and forward-looking vision for the future of healthcare. The rebranding follows a year of significant accomplishments for Click, including the FDA clearance of its first prescription digital therapeutic for the adjunctive treatment of major depressive disorder (MDD) symptoms, the successful CT-132 pivotal study for the preventive treatment of episodic migraine, and the launch of Click SE™, a new product offering. Additionally, Click completed a Series C financing round led by Dassault Systèmes and Medidata.
The updated brand celebrates Click’s role as an innovator at the intersection of medicine and technology, focusing on personalization, cutting-edge software, and a science-driven approach to treatment. By combining clinical science with the power of software, Click aims to bridge gaps in care and improve clinical outcomes. The brand refresh emphasizes the company’s multidisciplinary approach, positioning it as a leader in digital therapeutics, a growing field that uses software to address unmet medical needs.
“Click Therapeutics has seen remarkable growth in recent years, making significant strides in digital therapeutics and software-enhanced drug therapies while producing robust clinical data that proves their ability to improve patient outcomes,” said David Benshoof Klein, Founder and CEO of Click Therapeutics. “Our updated brand reflects who we are today and our vision for the future: enhancing the standard of care for patients with unmet medical needs.”
The rebranding includes the development of a new brand architecture and visual identity, designed to highlight Click’s commitment to personalization and innovation. This new identity is reflected in the company’s website, which has been designed with patient accessibility in mind, offering improved access to research, publications, and details about Click’s products. The use of the moiré effect in the design symbolizes the synergy created by merging traditionally separate fields—medicine and technology—and highlights the value that Click creates by combining these disciplines.
“Our updated brand reflects our ambition to explore innovative ways to deliver value to patients, physicians, and the broader healthcare ecosystem,” said Austin Speier, Chief Strategy Officer at Click, who led the rebranding initiative. “The new website also underscores our expansion into software-enhanced drug therapies, which build on our success in digital therapeutics. It serves as a platform for communicating our insights into artificial intelligence and patient-centered design.”
At the heart of the brand refresh is Click’s new offering, Click SE™, which combines its patented digital therapeutic technology with pharmacotherapy to create software-enhanced drug™ treatments in collaboration with pharmaceutical companies. These innovative therapies target the unique needs of specific medications and patient populations, offering added clinical benefits over traditional medications alone. Click SE™ represents a new frontier in personalized healthcare, offering combination therapies that can improve treatment outcomes for patients with complex conditions.
The rebranding also comes on the heels of Click’s successful Series C funding round, led by Dassault Systèmes. This investment will allow Click to further expand its collaboration with Medidata, a Dassault Systèmes brand, and leverage their global reach to accelerate the development of new therapies. Together, the companies aim to redefine clinical trial design and execution for digital therapeutics and software-enhanced drug™ treatments, ultimately advancing approval processes for therapeutic innovators worldwide.
The new website was developed in partnership with Base Design, an internationally recognized creative agency. Thomas Byttebier, Brussels Digital Director at Base Design, emphasized the importance of reflecting Click’s combination of deep scientific expertise and cutting-edge technology in the site’s design. “We wanted the website to be precise and credible, yet sleek and intuitive, reflecting Click’s role in shaping the future of digital medicine,” he said.
Click Therapeutics is redefining the possibilities of healthcare by developing prescription medical treatments that combine clinical science with software. The company’s platform enables the creation of clinically validated digital therapeutics, which are regulated mobile applications designed to address a variety of therapeutic needs, including in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases. Click’s first FDA-authorized digital therapeutic, Rejoyn™, was developed in collaboration with Otsuka and approved for the adjunctive treatment of MDD symptoms.
In response to FDA guidance on prescription drug use-related software (PDURS), Click launched Click SE™ in October 2024. This offering expands the company’s platform and expertise to include software-enhanced drug™ therapies, combining digital therapeutics with pharmacotherapy to provide added clinical benefits to patients. The launch of Click SE™ represents a significant step in the company’s ongoing mission to transform healthcare through the integration of technology and medicine.
Click is committed to advancing the field of digital medicine by continually improving its platform technologies. The company’s team of innovators—ranging from clinicians and researchers to technologists and designers—works together to create transformative digital therapeutics that aim to improve patient care and outcomes. With its refreshed brand identity, Click is poised to lead the way in the next generation of digital health solutions, offering personalized treatments that address some of the most pressing medical needs of our time.
